Fluphenazine decanoate Property

Melting point:

30-32°

Boiling point:

658.1±55.0 °C(Predicted)

Density 

1.149±0.06 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

Practically insoluble in water, very soluble in ethanol and in methylene chloride, freely soluble in methanol.

pka

7.32±0.10(Predicted)

CAS DataBase Reference

5002-47-1

Safety

RIDADR 

3249

RTECS 

HE0525000

HazardClass 

6.1(a)

PackingGroup 

II

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H300Fatal if swallowed

H361Suspected of damaging fertility or the unborn child

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

Fluphenazine decanoate Chemical Properties,Usage,Production

Chemical Properties

Yellow Oil

Uses

Fluphenazine Decanoate is used in psychotropic drug treatments like those relating to schizophrenia. Antipsychotic.

Definition

ChEBI: Fluphenazine decanoate is the prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia. It has a role as a phenothiazine antipsychotic drug, a prodrug and a dopaminergic antagonist. It is a member of phenothiazines, a decanoate ester, an organofluorine compound and a N-alkylpiperazine. It is functionally related to a fluphenazine.

Clinical Use

Antipsychotic
Schizophrenia and other psychoses

Drug interactions

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids.
Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; increased risk of ventricular arrhythmias with amiodarone and dronedarone - avoid; increased risk of ventricular arrhythmias with disopyramide.
Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin - avoid
Antidepressants: increased risk of ventricular arrhythmias with tricyclics, citalopram, escitalopram; possible increased risk of convulsions with vortioxetine
Antiepileptics: antagonises anticonvulsant effect.
Antimalarials: increased risk of ventricular arrhythmias with artenimol with piperaquine and artemether/lumefantrine - avoid.
Antipsychotics: increased risk of ventricular arrhythmias with droperidol, pimozide and risperidone - avoid; avoid use of depot formulations with clozapine (cannot be withdrawn quickly if neutropenia occurs).
Antivirals: increased risk of ventricular arrhythmias with saquinavir - avoid; concentration possibly increased with ritonavir.
Anxiolytics and hypnotics: increased sedative effects
Atomoxetine: increased risk of ventricular arrhythmias.
Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol
Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide
Diuretics: enhanced hypotensive effect.
Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
Pentamidine: increased risk of ventricular arrhythmias - avoid.
Avoid with drugs that prolong the QT interval.

Metabolism

The cytochrome P450 isoenzyme CYP2D6 is involved in fluphenazine metabolism.